Revolution Medicines (RVMD) Starts Phase 3 RASolute 309, Is It Still A Bargain?

Simply Wall St.10-10

AdvertisementWhy the RASolute 309 trial matters for Revolution Medicines Revolution Medicines (RVMD) has started treating patients in its RASolute 309 Phase 3 trial, testing RASONQUE with zoldonrasib ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2674995828?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","is_english":true,"pubTime":"2026-10-10 14:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2674995828","market":"sg","top_or_hot":-1,"title":"Revolution Medicines (RVMD) Starts Phase 3 RASolute 309, Is It Still A Bargain?","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhy the RASolute 309 trial matters for Revolution Medicines Revolution Medicines (RVMD) has started treating patients in its RASolute 309 Phase 3 trial, testing RASONQUE with zoldonrasib ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvmd/revolution-medicines/news/revolution-medicines-rvmd-starts-phase-3-rasolute-309-is-it\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Revolution Medicines (RVMD) Starts Phase 3 RASolute 309, Is It Still A Bargain?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRevolution Medicines (RVMD) Starts Phase 3 RASolute 309, Is It Still A Bargain?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-10 14:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvmd/revolution-medicines/news/revolution-medicines-rvmd-starts-phase-3-rasolute-309-is-it><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementWhy the RASolute 309 trial matters for Revolution Medicines Revolution Medicines (RVMD) has started treating patients in its RASolute 309 Phase 3 trial, testing RASONQUE with zoldonrasib ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvmd/revolution-medicines/news/revolution-medicines-rvmd-starts-phase-3-rasolute-309-is-it\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0320765992.SGD","symbol_name":"FTIF - Franklin Biotechnology Discovery A Acc SGD","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvmd/revolution-medicines/news/revolution-medicines-rvmd-starts-phase-3-rasolute-309-is-it","article_id":"2674995828","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvmd/revolution-medicines/news/revolution-medicines-rvmd-starts-phase-3-rasolute-309-is-it","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2674995828","pubTimestamp":1791613755,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Why the RASolute 309 trial matters for Revolution Medicines\nRevolution Medicines (RVMD) has started treating patients in its RASolute 309 Phase 3 trial, testing RASONQUE with zoldonrasib as a first-line option for metastatic RAS G12D pancreatic cancer.\nThe study compares this combination against standard chemotherapy gemcitabine and nab paclitaxel, with progression free survival and overall survival as dual primary endpoints that investors will watch closely.\nRevolution Medicines sits at...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","IE00BFMHRM44.USD":"NEUBERGER BERMAN GLOBAL EQUITY MEGATRENDS \"A\" (USD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","IE00BD6J9T35.USD":"NEUBERGER BERMAN NEXT GENERATION MOBILITY \"A\" (USD) ACC","LU1854103824.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) INC","PTH":"Invesco Dorsey Wright Healthcare Momentum ETF","BK4141":"半导体产品","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1983260115.SGD":"Janus Henderson Horizon Global Sustainable Equity A2 SGD-H","BK4588":"碎股","BK4605":"半导体精选","BBH":"VanEck Biotech ETF","ONG":"Leverage Shares 2X Long ON Daily ETF","LU1861214812.USD":"Blackrock Future of Transport A2 USD","IE00BZ199S13.USD":"BNY MELLON MOBILITY INNOVATION \"B\" (USD) ACC","BK4585":"ETF&股票定投概念","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0348723411.USD":"ALLIANZ GLOBAL HI-TECH GROWTH \"A\" (USD) INC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU1861219969.SGD":"Blackrock Future of Transport A2 SGD-H","IDNA":"iShares Genomics Immunology and Healthcare ETF","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","BK4139":"生物科技","ON":"安森美半导体","CANC":"TEMA ONCOLOGY ETF","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU1854104046.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1548497426.USD":"安联环球人工智能AT Acc","LU1861215975.USD":"贝莱德新一代科技基金 A2","RVMD":"Revolution Medicines, Inc.","LU2360107325.USD":"BGF FUTURE OF TRANSPORT \"A4\" (USD) INC","LU1861220033.SGD":"Blackrock Next Generation Technology A2 SGD-H","LU0124384867.USD":"贝莱德新能源基金A2","BK4512":"苹果概念","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","LU2298322129.HKD":"BGF SUSTAINABLE ENERGY \"A2\" (HKDHDG) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","ONX":"Tradr 2X Long ON Daily ETF","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0724618433.USD":"BGF NEW ENERGY \"A4\" (USD) INC","LU1978683503.SGD":"Blackrock Sustainable Energy A2 SGD-H"},"translate_title":"Revolution Medicines (RVMD) 开始 3 期 RASolute 309，还便宜吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BBH":0.6,"RVMD":1.5,"CANC":0.6,"ON":1,"ONG":0.6,"PTH":0.6,"ONX":0.6,"IDNA":0.6},"content_text":"AdvertisementWhy the RASolute 309 trial matters for Revolution Medicines Revolution Medicines (RVMD) has started treating patients in its RASolute 309 Phase 3 trial, testing RASONQUE with zoldonrasib as a first-line option for metastatic RAS G12D pancreatic cancer. The study compares this combination against standard chemotherapy gemcitabine and nab paclitaxel, with progression free survival and overall survival as dual primary endpoints that investors will watch closely. Revolution Medicines sits at US$189.76 after a 1-day share price return of 0.87%. However, the 7-day and 30-day share price returns are down 8.17% and 8.63%, hinting at cooling short-term momentum after a strong year-to-date share price gain of 140.14% and a 1-year total shareholder return of 293.37% that builds on very large 3-year and 5-year total shareholder return figures. Scan beyond Revolution Medicines and identify other high conviction oncology players using the curated 20 high quality undiscovered gems that is aligned with similar high-impact clinical pipelines. Revolution Medicines has rallied hard yet now trades well below the average analyst estimate, so where might a reasonable fair value range actually sit after this latest move? Most Popular Narrative: 26% Undervalued On the most followed view, Revolution Medicines screens as undervalued, with a fair value of $257.47 against the last close at $189.76. This sets a high bar for what the RASolute 309 and broader RAS program need to deliver.  The move toward targeted oncology treatments for high unmet need tumors such as pancreatic, lung and colorectal cancer aligns with the company’s RAS(ON) portfolio. This could influence long term revenue growth if multiple registrational programs convert to approved therapies. Eight ongoing or planned Phase III registrational trials and clinical experience in more than 2,500 patients create multiple data points over the next few years. These could change how investors view the durability and scale of the pipeline, with potential implications for future revenue visibility and earnings power.  See why 15 investors see Revolution Medicines as 26% undervalued. Result: Fair Value of $257.47 (UNDERVALUED) Still, the Revolution Medicines story could change quickly if high cost R&D fails to translate into approvals, or if RAS focused trials deliver weaker than expected data. Find out about the key risks to this Revolution Medicines narrative. Another View: Revolution Medicines on traditional multiples Analyst models and SWS fair value work suggest Revolution Medicines looks cheap against future cash flow, yet the current P/B of 15.6x is far above the US Biotechs average of 2.1x and above peer levels of 12.5x. If the market leans back toward those benchmarks, how comfortable are you with that valuation swing? For a closer look at what the current ratio says about valuation risk versus upside, take a moment with See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:RVMD P/B Ratio as at Oct 2026Next Steps Mixed messages in the Revolution Medicines story today. For a clear take, move quickly, review the data, and weigh both sides by examining the 3 key rewards and 2 important warning signs. Looking for more Revolution Medicines style investment ideas? Revolution Medicines offers one angle on high impact oncology, but building a resilient portfolio means lining up a few different sources of potential return across sectors. Use the Simply Wall St Screener to uncover other stocks with strong fundamentals, distinctive return profiles and balance sheets that can handle tougher conditions without falling apart.  Target mispriced quality and let the numbers guide you toward potential value opportunities with the 28 high quality undervalued stocks. Prioritise staying power and protect your downside by focusing on companies highlighted in the 31 resilient stocks with low risk scores. Strengthen your core holdings by concentrating on financially robust businesses sourced from the list of solid balance sheet and fundamentals (25 results).   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2674995828","isCrawlerRequest":true}